Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel PET tracers to distinguish the nature of residual masses after the completion of chemotherapy in metastatic testicular germ cell tumours: A systematic review.

European journal of nuclear medicine and molecular imaging·2026
Same author

Drug-loaded biomorphic scaffolds for tissue regeneration and targeted antitumor therapy in bone metastasis models.

Biomaterials advances·2026
Same author

Splenic FDG PET uptake and CT volume as prognostic biomarkers in diffuse large B cell lymphoma.

La Radiologia medica·2026
Same author

Impact of PSMA-Based Radiopharmaceuticals on the Clinical Management of Prostate Cancer.

Cancers·2026
Same author

FAPI PET in inflammatory bowel disease: a novel window on fibroblast activity, with unanswered clinical questions.

Expert review of gastroenterology & hepatology·2026
Same author

Cancer-associated and non-neoplastic fibrosis: Comparative mechanisms and emerging antifibrotic strategies.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026

Related Experiment Video

Updated: Jun 27, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K

PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality?

Luca Urso1, Luca Filippi2, Angelo Castello3

  • 1Department of Nuclear Medicine-PET/CT Center, S. Maria della Misericordia Hospital, 45100 Rovigo, Italy.

Journal of Clinical Medicine
|November 25, 2023
PubMed
Summary
This summary is machine-generated.

Prostate-specific membrane antigen (PSMA) ligand PET improves detection rates in castration-resistant prostate cancer (CRPC) but has limitations. Integrated multi-tracer imaging may enhance precision medicine for CRPC patients.

Keywords:
FDG PETPCaPSMA PETUBUcastration-resistant prostate cancerpitfallsprostate cancersecond primary neoplasm

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.1K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K

Related Experiment Videos

Last Updated: Jun 27, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.1K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiomics

Background:

  • Prostate-specific membrane antigen (PSMA) ligand PET is increasingly used for prostate cancer (PCa).
  • Its role in castration-resistant prostate cancer (CRPC) requires further clarification.
  • Current guidelines recommend PSMA ligand PET for specific PCa indications.

Purpose of the Study:

  • To evaluate the clinical utility of PSMA ligand PET/CT in CRPC patients.
  • To assess the diagnostic performance of PSMA ligand PET in CRPC.
  • To explore strategies for improving diagnostic accuracy in CRPC.

Main Methods:

  • Review of clinical data and imaging findings in CRPC patients.
  • Comparison of PSMA ligand PET/CT with conventional imaging modalities.
  • Analysis of limitations and potential improvements for PSMA ligand PET in CRPC.

Main Results:

  • PSMA ligand PET/CT shows higher detection rates than conventional imaging in CRPC.
  • It can reduce the number of patients classified as M0 CRPC.
  • Limitations include potential false positives (e.g., UBU, SNPs) and false negatives due to tumor heterogeneity (PSMA-/FDG+ or vice versa).

Conclusions:

  • PSMA ligand PET/CT offers improved detection but has sensitivity and specificity challenges in CRPC.
  • Integrated multi-tracer imaging (e.g., PSMA and FDG PET) is proposed to enhance diagnostic accuracy.
  • A multidisciplinary approach combined with multi-tracer imaging supports precision medicine for CRPC management.